Developer docs
API playgroundTry for free, no card

Search company profiles

Prothea Technologies

Full company profile

uuid00028vx

Namestring
Prothea Technologies
Legal namestring
Prothea Technologies Ltd.
Websiteurl
prothea.tech
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Prothea Technologies is a medical device spinout from the Universities of Edinburgh and Bath, founded to enable lung cancer biopsy and treatment within a single hospital visit. The company is developing a fiber-optic microendoscope combined with an AI-enhanced Image Processing System based on fluorescence lifetime imaging (FLIM), which measures the differential time for light to travel between healthy and abnormal lung tissue at the molecular level. In clinical samples, the technology achieved 81.0% sensitivity and 71.4% specificity in distinguishing cancerous from non-cancerous tissue. A complementary therapeutic laser ablation catheter is in development, intended to allow immediate lesion treatment following imaging and biopsy.

The company operates from three primary locations: Edinburgh (headquarters and clinical trial site at the Royal Infirmary of Edinburgh), Bath (R&D and fiber fabrication in partnership with the University of Bath's Fibre Fabrication Facility), and Cologne/Bergisch Gladbach (manufacturing operations via Prothea Technologies GmbH). It maintains a US presence led by an SVP based in the Bay Area. Prothea is pre-commercial and is currently running the First-In-Human Precision Lung clinical study (ISRCTN15093468), co-sponsored with the University of Edinburgh and NHS Lothian, recruiting up to 40 patients to generate safety, procedural success, and biopsy yield data for regulatory submission and clinical adoption.

The business model is hardware-led (microendoscope, laser ablation catheter) with a potential subscription or licensing layer for AI software upgrades derived from anonymised clinical imaging data. Pricing has not been disclosed, and go-to-market is anticipated as direct enterprise sales to tertiary and quaternary hospitals with interventional pulmonology departments, supported by KOL endorsements and conference-driven awareness (AABIP, ECBIP). The company has assembled a PhD-heavy team across clinical, optical, and AI disciplines and is backed by a €12M Series A co-led by Earlybird Venture Capital and Mérieux Equity Partners, with non-dilutive funding from Wellcome, Cancer Research UK, CARB-X, and UKRI/EPSRC.

Short descriptiontext

Prothea Technologies is a UK-based medical device spinout developing a fiber-optic microendoscope with AI-enhanced fluorescence lifetime imaging for real-time lung cancer biopsy and ablation. The company targets interventional pulmonology departments at tertiary hospitals to enable single-visit diagnosis and treatment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEdinburgh, United Kingdom
HQ citystring
Edinburgh
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
interventional pulmonology devices, lung cancer biopsy systems, fluorescence lifetime imaging, medical fiber-optic endoscopy, laser ablation catheters
Industry5 codes
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHANAG
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAOAA
Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Interventional Pulmonology Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales (Imaging and Biopsy System)
TypeHardware Sales
Description

Sale of the Prothea Microendoscope combined with an Image Processing System to hospitals and interventional pulmonology departments. The system consists of hardware (fibre-based imaging catheter) and software (image processing/AI analysis). Revenue will be generated upon regulatory approval and commercial launch.

prothea.tech
2Laser Ablation Catheter
TypeHardware Sales
Description

Sale of therapeutic laser ablation catheter for immediate lesion treatment following imaging and biopsy. Planned as a complementary product to the imaging system, enabling single-visit biopsy and treatment.

prothea.tech
3Software Upgrades and AI Enhancements
TypeSubscription Recurring
Description

Ongoing software upgrades incorporating AI algorithms developed from anonymised imaging data sets acquired in clinical studies. Potential for subscription or licence-based revenue from software enhancements.

prothea.tech
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Prothea Technologies develops a medical device platform centred on a miniaturised fibre-optic microendoscope combined with an AI-enhanced Image Processing System that uses fluorescence lifetime imaging (FLIM) to differentiate cancerous from healthy lung tissue in real time during bronchoscopy. A therapeutic Laser Ablation Catheter is in development to enable integrated biopsy and treatment of lung cancer in a single hospital visit. The platform is currently pre-commercial, undergoing First-In-Human clinical trials at the Royal Infirmary of Edinburgh.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • FLIM achieved 81.0% sensitivity and 71.4% specificity in distinguishing lung cancer from healthy tissue in resected samples from 21 patients
+3 more records
Product overview1 text field

Prothea Technologies offers a unified medical device platform for lung cancer diagnosis and treatment, consisting of a Microendoscope combined with an Image Processing System, with a Laser Ablation Catheter in development. The platform enables biopsy and treatment of lung cancer in a single hospital visit, reducing time-to-treat from weeks to minutes. The Microendoscope provides real-time in situ analysis of lung lesion structure at the molecular level, working alongside biopsy instruments. The proprietary Image Processing System uses AI-enhanced software to analyse fluorescence lifetime imaging data and support clinical decisions. The Laser Ablation Catheter is being developed for immediate lesion treatment following imaging and biopsy. Additionally, clinic-ready prototypes of disposable Micro-Bronchoscopes have been developed through partnership with University of Bath. The company also has a separate clinical program for lung infection detection in ICU patients supported by Wellcome.

Product and service4 records
1Microendoscope
CategoryImaging and Biopsy Device
Description

A miniaturised flexible fibre-optic microendoscope that combines with the Image Processing System to characterise lung lesions in situ at the molecular level using fluorescence lifetime imaging (FLIM), providing real-time imaging alongside biopsy tools for improved diagnostic accuracy during bronchoscopy.

2Image Processing System
CategoryMedical Imaging Software
Description

Proprietary AI-enhanced software system that measures the differential in time between healthy and abnormal tissue for the round trip of light from a laser source, using a ResNetZ CNN architecture to evaluate large volume FLIM data sets and provide real-time in-procedure clinical decision support for distinguishing cancerous from non-cancerous lung tissue.

3Laser Ablation Catheter
CategoryTherapeutic Catheter Device
Description

Therapeutic catheter in development for the treatment of lung lesions immediately following visualisation and biopsy using the Prothea imaging system, designed to enable integrated biopsy and treatment in a single hospital visit.

4Micro-Bronchoscopes
CategoryDisposable Endoscopic Devices
Description

Disposable imaging fibres developed in partnership with the University of Bath's Fibre Fabrication Facility using 'stack and draw' techniques, designed to overcome challenges including high costs, sterilisation requirements, and cross-contamination risks of reusable endoscopes in clinical workflows.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Collaboration with University of Bath's Fibre Fabrication Facility to develop affordable optical fibres tailored for healthcare and medical imaging applications. The partnership uses 'stack and draw' techniques inspired by telecommunications to create disposable imaging devices. Yields clinic-ready prototypes for micro-bronchoscopes and established a dedicated branch at the university with access to fibre-drawing towers.

2University of Edinburgh
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spinout university and co-sponsor of the Precision Lung clinical study (ISRCTN15093468) through ACCORD, the joint research office between the University of Edinburgh and NHS Lothian. Prof. Kev Dhaliwal serves as Chief Medical and Scientific Officer. Multiple patents licensed from the university.

prothea.tech
3ACCORD (University of Edinburgh and NHS Lothian)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint research office co-sponsoring the Precision Lung clinical study. Prothea provided technology as part of a collaboration agreement with the University of Edinburgh. Study being conducted at Royal Infirmary of Edinburgh.

prothea.tech
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-sponsor of the Precision Lung clinical study through ACCORD. Dr. Adam Marshall, Consultant Interventional Pulmonologist at Royal Infirmary of Edinburgh, serves as Principal Investigator.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Listed as a partner on the Prothea website. California Life Sciences is a trade association for the life sciences industry in California.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prothea Technologies

Interventional Pulmonology Medical Devicesprothea.tech

Prothea Technologies is a UK-based medical device spinout developing a fiber-optic microendoscope with AI-enhanced fluorescence lifetime imaging for real-time lung cancer biopsy and ablation. The company targets interventional pulmonology departments at tertiary hospitals to enable single-visit diagnosis and treatment.

What Prothea Technologies does

Prothea Technologies is a medical device spinout from the Universities of Edinburgh and Bath, founded to enable lung cancer biopsy and treatment within a single hospital visit. The company is developing a fiber-optic microendoscope combined with an AI-enhanced Image Processing System based on fluorescence lifetime imaging (FLIM), which measures the differential time for light to travel between healthy and abnormal lung tissue at the molecular level. In clinical samples, the technology achieved 81.0% sensitivity and 71.4% specificity in distinguishing cancerous from non-cancerous tissue. A complementary therapeutic laser ablation catheter is in development, intended to allow immediate lesion treatment following imaging and biopsy.

The company operates from three primary locations: Edinburgh (headquarters and clinical trial site at the Royal Infirmary of Edinburgh), Bath (R&D and fiber fabrication in partnership with the University of Bath's Fibre Fabrication Facility), and Cologne/Bergisch Gladbach (manufacturing operations via Prothea Technologies GmbH). It maintains a US presence led by an SVP based in the Bay Area. Prothea is pre-commercial and is currently running the First-In-Human Precision Lung clinical study (ISRCTN15093468), co-sponsored with the University of Edinburgh and NHS Lothian, recruiting up to 40 patients to generate safety, procedural success, and biopsy yield data for regulatory submission and clinical adoption.

The business model is hardware-led (microendoscope, laser ablation catheter) with a potential subscription or licensing layer for AI software upgrades derived from anonymised clinical imaging data. Pricing has not been disclosed, and go-to-market is anticipated as direct enterprise sales to tertiary and quaternary hospitals with interventional pulmonology departments, supported by KOL endorsements and conference-driven awareness (AABIP, ECBIP). The company has assembled a PhD-heavy team across clinical, optical, and AI disciplines and is backed by a €12M Series A co-led by Earlybird Venture Capital and Mérieux Equity Partners, with non-dilutive funding from Wellcome, Cancer Research UK, CARB-X, and UKRI/EPSRC.

Prothea Technologies firmographics

Firmographics
Name
Prothea Technologies
Legal name
Prothea Technologies Ltd.
Website
https://prothea.tech
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Prothea Technologies is a UK-based medical device spinout developing a fiber-optic microendoscope with AI-enhanced fluorescence lifetime imaging for real-time lung cancer biopsy and ablation. The company targets interventional pulmonology departments at tertiary hospitals to enable single-visit diagnosis and treatment.
Ownership category
akta.pro rank

Prothea Technologies industry classification

Industry
Product category
Interventional Pulmonology Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHANAG
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAOAA
Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Interventional pulmonology devices
  • Lung cancer biopsy systems
  • Fluorescence lifetime imaging
  • Medical fiber-optic endoscopy
  • Laser ablation catheters

Where Prothea Technologies is headquartered

Location

Headquarters

HQ city
Edinburgh
HQ country
United Kingdom
HQ region
Europe

Offices5 records

Markets served

Prothea Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales (Imaging and Biopsy System): Sale of the Prothea Microendoscope combined with an Image Processing System to hospitals and interventional pulmonology departments. The system consists of hardware (fibre-based imaging catheter) and software (image processing/AI analysis). Revenue will be generated upon regulatory approval and commercial launch.
  2. Laser Ablation Catheter: Sale of therapeutic laser ablation catheter for immediate lesion treatment following imaging and biopsy. Planned as a complementary product to the imaging system, enabling single-visit biopsy and treatment.
  3. Software Upgrades and AI Enhancements: Ongoing software upgrades incorporating AI algorithms developed from anonymised imaging data sets acquired in clinical studies. Potential for subscription or licence-based revenue from software enhancements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Prothea Technologies product offering

Product offering

Core offering

Prothea Technologies develops a medical device platform centred on a miniaturised fibre-optic microendoscope combined with an AI-enhanced Image Processing System that uses fluorescence lifetime imaging (FLIM) to differentiate cancerous from healthy lung tissue in real time during bronchoscopy. A therapeutic Laser Ablation Catheter is in development to enable integrated biopsy and treatment of lung cancer in a single hospital visit. The platform is currently pre-commercial, undergoing First-In-Human clinical trials at the Royal Infirmary of Edinburgh.

Product overview

Prothea Technologies offers a unified medical device platform for lung cancer diagnosis and treatment, consisting of a Microendoscope combined with an Image Processing System, with a Laser Ablation Catheter in development. The platform enables biopsy and treatment of lung cancer in a single hospital visit, reducing time-to-treat from weeks to minutes. The Microendoscope provides real-time in situ analysis of lung lesion structure at the molecular level, working alongside biopsy instruments. The proprietary Image Processing System uses AI-enhanced software to analyse fluorescence lifetime imaging data and support clinical decisions. The Laser Ablation Catheter is being developed for immediate lesion treatment following imaging and biopsy. Additionally, clinic-ready prototypes of disposable Micro-Bronchoscopes have been developed through partnership with University of Bath. The company also has a separate clinical program for lung infection detection in ICU patients supported by Wellcome.

Differentiator

Problem solved

Functional benefit

Products and services

  • Microendoscope A miniaturised flexible fibre-optic microendoscope that combines with the Image Processing System to characterise lung lesions in situ at the molecular level using fluorescence lifetime imaging (FLIM), providing real-time imaging alongside biopsy tools for improved diagnostic accuracy during bronchoscopy.
  • Image Processing System Proprietary AI-enhanced software system that measures the differential in time between healthy and abnormal tissue for the round trip of light from a laser source, using a ResNetZ CNN architecture to evaluate large volume FLIM data sets and provide real-time in-procedure clinical decision support for distinguishing cancerous from non-cancerous lung tissue.
  • Laser Ablation Catheter Therapeutic catheter in development for the treatment of lung lesions immediately following visualisation and biopsy using the Prothea imaging system, designed to enable integrated biopsy and treatment in a single hospital visit.
  • Micro-Bronchoscopes Disposable imaging fibres developed in partnership with the University of Bath's Fibre Fabrication Facility using 'stack and draw' techniques, designed to overcome challenges including high costs, sterilisation requirements, and cross-contamination risks of reusable endoscopes in clinical workflows.

Quantifiable outcome

  • FLIM achieved 81.0% sensitivity and 71.4% specificity in distinguishing lung cancer from healthy tissue in resected samples from 21 patients
  • +3 more outcomes

Companies that use Prothea Technologies

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Prothea Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Prothea Technologies partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • University of BathcoreStrategic or Co-development Partner · 1 February 2025Collaboration with University of Bath's Fibre Fabrication Facility to develop affordable optical fibres tailored for healthcare and medical imaging applications. The partnership uses 'stack and draw' techniques inspired by telecommunications to create disposable imaging devices. Yields clinic-ready prototypes for micro-bronchoscopes and established a dedicated branch at the university with access to fibre-drawing towers.
  • University of EdinburghcoreStrategic or Co-development PartnerSpinout university and co-sponsor of the Precision Lung clinical study (ISRCTN15093468) through ACCORD, the joint research office between the University of Edinburgh and NHS Lothian. Prof. Kev Dhaliwal serves as Chief Medical and Scientific Officer. Multiple patents licensed from the university.
  • ACCORD (University of Edinburgh and NHS Lothian)coreStrategic or Co-development PartnerJoint research office co-sponsoring the Precision Lung clinical study. Prothea provided technology as part of a collaboration agreement with the University of Edinburgh. Study being conducted at Royal Infirmary of Edinburgh.
  • NHS LothiancoreStrategic or Co-development PartnerCo-sponsor of the Precision Lung clinical study through ACCORD. Dr. Adam Marshall, Consultant Interventional Pulmonologist at Royal Infirmary of Edinburgh, serves as Principal Investigator.
  • California Life SciencesminorGTM or Marketing PartnerListed as a partner on the Prothea website. California Life Sciences is a trade association for the life sciences industry in California.

Scale indicators4 records

Recent moves10 records

Expansion highlights6 records

Prothea Technologies competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Prothea Technologies social profiles

Digital presence

Prothea Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prothea Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Prothea Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prothea Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prothea Technologies

What does Prothea Technologies do?

Prothea Technologies develops a medical device platform centred on a miniaturised fibre-optic microendoscope combined with an AI-enhanced Image Processing System that uses fluorescence lifetime imaging (FLIM) to differentiate cancerous from healthy lung tissue in real time during bronchoscopy. A therapeutic Laser Ablation Catheter is in development to enable integrated biopsy and treatment of lung cancer in a single hospital visit. The platform is currently pre-commercial, undergoing First-In-Human clinical trials at the Royal Infirmary of Edinburgh.

Is Prothea Technologies a public or private company?

Prothea Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prothea Technologies founded?

Prothea Technologies was founded in 2024. It employs 11 to 50 people.

Where is Prothea Technologies based?

Prothea Technologies is headquartered in Edinburgh, United Kingdom, in the Europe region.

How does Prothea Technologies make money?

Three revenue lines are on record. Medical Device Sales (Imaging and Biopsy System) is the primary driver. The others are laser Ablation Catheter and software Upgrades and AI Enhancements.

Does Prothea Technologies have an API?

No public API is recorded for Prothea Technologies.

What industry is Prothea Technologies in?

Prothea Technologies's product category is Interventional Pulmonology Medical Devices. Its primary akta.pro industry code is HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence), with a secondary code of HLAHANAG, Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals